Table 2.

Allele frequency of activating and resistant EGFR mutations

PatientAge, ySexHistologyStageT790M, %Activating mutation, %T790M/activating mutation, %Activating mutation type
A. Group 1 (patients with PD after EGFR-TKI treatment)
156Madeno40.0290.05850.8L861Q
258Fadeno40.260.2894.0L858R
370Fadeno42.617.3935.3L858R
478Madeno3A0.080.1365.0L858R
565MAdeno + Sq40.631.1057.6L858R
620MAdeno40.141.0313.3exon 19 E746-A750del
741Fadeno44.2810.341.6exon 19 E746-A750del
859Fadeno49.5442.722.3exon 19 E746-A750del
953Madeno40.160.1983.6exon 19 E746-A750del
1049Fadeno4ND0.120.0L861Q
1175Fadeno4ND2.030.0L858R
1234Madeno4ND0.330.0L858R
1364Madeno4ND12.20.0L858R
1473Fadeno4ND0.0460.0L858R
1566Fadeno4ND0.280.0exon 19 L747-S752del.P753S
1670Madeno4ND11.50.0exon 19 L747-S752del.P753S
1744Fadeno4ND0.090.0exon 19 L747-E749del.A750P
1852Madeno4ND0.740.0exon 19 L747-E749del.A750P
1974Fadeno4ND0.330.0exon 19 E746-A750del
2063Fadeno4NDNDNAL858R
2165Fadeno40.10NDNAexon 19 E746-A750del
2251Fadeno4NDNDNAexon 19 E746-A750del
2362Fadeno4NDNDNAexon 19 E746-A750del
B. Group 2 (patients not treated with EGFR-TKI)
2468Madeno4ND0.170.0L858R
2545Fadeno4ND0.230.0L858R
2685Fadeno2BND0.250.0L858R
2767Fadeno4ND0.0790.0L858R
2858Fadeno4ND0.0130.0L858R
2939Fadeno3BND36.40.0L858R
3036Fadeno4ND0.110.0exon 19 L747-S752del.E746V
3156Madeno4ND6.470.0exon 19 L747-T751del.S752Q
3255Fadeno3AND6.240.0exon 19 L747-E749del.A750P
3365Fadeno3BND11.80.0exon 19 E746-A750del
3476Fadeno4ND1.060.0exon 19 E746-A750del
3563FSq4ND0.730.0exon 19 E746-A750del
3663Madeno4ND0.0300.0exon 19 E746-L747del.IP
3772Fadeno4NDNDNAL858R
3870Fadeno4NDNDNAL858R
3963Madeno4NDNDNAL858R
4080Fadeno4NDNDNAL858R
4170Fadeno4NDNDNAL858R
4272Madeno40.03NDNAexon 19 L747-S752del.P753S
4347Madeno4NDNDNAexon 19 E746-A750del
4454Fadeno4NDNDNAexon 19 E745-E749del.A750K

Abbreviations: NA, not applicable; ND, not detected.